Itro, A.; Trotta, M.C.; Miranda, R.; Paoletta, M.; De Cicco, A.; Lepre, C.C.; Tarantino, U.; D’Amico, M.; Toro, G.; Schiavone Panni, A.
Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review. Pharmaceutics 2022, 14, 1151.
https://doi.org/10.3390/pharmaceutics14061151
AMA Style
Itro A, Trotta MC, Miranda R, Paoletta M, De Cicco A, Lepre CC, Tarantino U, D’Amico M, Toro G, Schiavone Panni A.
Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review. Pharmaceutics. 2022; 14(6):1151.
https://doi.org/10.3390/pharmaceutics14061151
Chicago/Turabian Style
Itro, Annalisa, Maria Consiglia Trotta, Roberta Miranda, Marco Paoletta, Annalisa De Cicco, Caterina Claudia Lepre, Umberto Tarantino, Michele D’Amico, Giuseppe Toro, and Alfredo Schiavone Panni.
2022. "Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review" Pharmaceutics 14, no. 6: 1151.
https://doi.org/10.3390/pharmaceutics14061151
APA Style
Itro, A., Trotta, M. C., Miranda, R., Paoletta, M., De Cicco, A., Lepre, C. C., Tarantino, U., D’Amico, M., Toro, G., & Schiavone Panni, A.
(2022). Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review. Pharmaceutics, 14(6), 1151.
https://doi.org/10.3390/pharmaceutics14061151